Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-03-22
2011-03-22
Li, Q. Janice (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C435S455000
Reexamination Certificate
active
07910565
ABSTRACT:
Androgen receptor-based vaccines for eliciting an immune reaction in vivo against cells expressing androgen receptor are disclosed. The vaccines are useful in the treatment of prostate cancer. Also disclosed are methods for inducing immune reaction to androgen receptor or treating prostate cancer in a mammal, using the vaccines and pharmaceutical compositions comprising the vaccines.
REFERENCES:
patent: 6548064 (2003-04-01), Tureci et al.
patent: 6800730 (2004-10-01), Tureci et al.
patent: 7179797 (2007-02-01), McNeel et al.
patent: 2004/0142890 (2004-07-01), McNeel et al.
Eder et al. Future Oncol 2005;1:93-101.
Scher et al. Endocrine-Related Cancer 2004;11:459-76.
Chen et al. Nat Med 2004;10:33-9.
Olson et al. Prostate 2007;1729-39.
Suarez-Quian et al. J Clin Endocrinol Metab 1999;84:350-8.
Chichet et al. Int J Morphol 2007;25:579-85.
Meidenbauer et al., Direct visualization of antigen-specific T cells using peptide-MHC-class I tetrameric complexes, Methods 31 (2003): 160-171.
Palmowski, et al., The use of HLA class I tetramers to design a vaccination strategy for melanoma patients, Immunological Reviews 188 (2002): 155-163.
Mincheff M, Tchakarov S, Zoubak S, et al, Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer; a phase I/II clinical trial. Eur Urol. 2000:38:208-217.
Irvine and Restifo, 1995, Seminars in Canc. Biol. 6:337-347.
Iwasaki A, Torres C A, Ohashi P S, Robinson H L, Barber B H. J Immunol. 1997;159:11-4.
Chen et al., 1998, Induction of CD8+ T Cell Responses to Dominant and Subdominant Epitopes and Protective Immunity to Sendai Virus Infection by DNA Vaccination. J. Immunol. 160:2425-2432.
Thomson et al., 1998, Delivery of Multiple CD8 Cytotoxic T Cell Epitopes by DNA Vaccination, J. Immunol. 160:1717-1723.
Cho et al., 2000, Nat. Biotechnol, 18:509-14.
Wolff et al., 1990, Direct Gene Transfer into Mouse Muscle In Vivo, Science 247-1465-8.
Tighe et al., 1998, Gene vaccination: plasmid DNA is more than just a blueprint, Immunol. Today 19:89-97.
Raz E, Carson DA, Parker SE, Parr TB, Abai AM, Aichinger G. Gromkowski SH, Singh M. Lew D, Yankauckas MA: Intradermal gene immunization: The possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci USA 1994, 91:9519-23.
Lee, A. H., Y. S. Suh, J. H. Sung, S. H. Yang, and Y. C. Sung 1997. Comparison of various expression plasmids for the induction of immune response by DNA immunization. Mol. Cell 7:495-501.
Hartmann G, Weeratna RD, Belles ZK et al. Delineation of a CpG phosphorothioate oligodeoxinucleotide for activating primate immune responses in vitro and in vivo. J Immunol 2000, 164: 1617-24.
Acsadi et al., 1991, Direct gene transfer and expression into rat heart in vivo, New Biol. 3:71-81.
Wolff et. al., 1991, Conditions Affecting Direct Gene Transfer into Rodent Muscle in Vivo, Biotechniques 11(4):474-85.
Budker et. al., 1996, Nat. Biotechnol, 14:760-4.
Davis HL, Whalen RG, Demeneix BA. Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression. Hum Gene Ther 1993;4:151-9.
Danko et al., 1994, Gene Ther. 1:114-21.
Manthorpe et al., Gene Therapy by Intramuscular Injection of Plasmid DNA: Studies on Firefly Luciferase Gene Expression in Mice, Hum. Gene Ther. 4:419-31 (1993).
Budker et al., 1996, Naked DNA delivered intraportally expresses efficiently in hepatocytes, Gene Ther. 3:593-8.
Budker et al., 1998, The efficient expression intravascularly delivered DNA in rat muscle. Gene Ther. 5:272-276.
Zhang G et al. Efficient expression of naked DNA delivered intraarterially to limb muscles of nonhuman primates. Hum Gene Ther 2001; 12: 427-438.
Wagner et al., 2003. Cancer lmrun 3:18-32.
Maha Ayyoub, Charles S. Hesdorffer, Genevieve Matthez, Stefan Stevanovic, Gerd Ritter, Yao-Tseng Chen, Lloyd J. Old, Daniel Speiser, Jean-Charles Cerottini, Danila Valmori. (2004) identification of an SSX-2 Epitope Presented by Dendritic Cells to circulating Autologous CD4+ T Cells, J. of Immunol. 172:7206-11.
Tureci O, Sahin U, Zwick C. Koslowski M, Seitz G, Pfreundschuh M. Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc Natl Acad Sci U S A 1998: 95: 5211-6.
Scanlan M.J. et al., The cancer/testis genes: review, standardization, and commentary (2004) Cancer Immun, 4:1.
Abstract, Prikler L. et al., 2004, Adaptive Immunotherapy of the Advanced Prostate Cancer—Cancer Testis Antigen (CTA) as Possible Target Antigens, Klinische Originalarbeit 35:326-330.
Kaplan-Lefko P. J., Chen T. M., Ittmann M. M., Barrios R. J., Ayala G. E., Huss W. J., Maddison L. A., Foster B. A., and Greenberg N. M. (2003) “Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model.” Prostate 55:219-237.
McNeel Douglas G.
Olson Brian M.
Li Q. Janice
Quarles & Brady LLP
Wisconsin Alumni Research Foundation
LandOfFree
Prostate cancer vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prostate cancer vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prostate cancer vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2696622